MetaVia Inc. (MTVA)
| Market Cap | 9.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.22M |
| Shares Out | 3.21M |
| EPS (ttm) | -11.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 617,279 |
| Open | 3.340 |
| Previous Close | 3.110 |
| Day's Range | 2.950 - 3.398 |
| 52-Week Range | 2.950 - 23.540 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 68.33 (+2,097.11%) |
| Earnings Date | Nov 6, 2025 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MTVA stock is "Strong Buy." The 12-month stock price target is $68.33, which is an increase of 2,097.11% from the latest price.
News
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ann...
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
CAMBRIDGE, Mass., Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ann...
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic Res...
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
CAMBRIDGE, Mass. , Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will part...
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December ...
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
CAMBRIDGE, Mass. , Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles CAMBRIDGE, Mass. , Nov. ...
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expec...
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
New Phase 1 PK Data Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration DA-1726 Achieves Superior Lipid-Lowering Effects and Comparable Weight Loss to Pemvidu...
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
CAMBRIDGE, Mass. , Oct. 27, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract ...
MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025
CAMBRIDGE, Mass. , Oct. 20, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that two abstract...
MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
CAMBRIDGE, Mass. , Oct. 14, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President an...
MetaVia to Present at Upcoming Investor and Industry Conferences
CAMBRIDGE, Mass. , Aug. 26, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation...
MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected in the Fo...
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
Extension is Designed to Assess Early Efficacy and Patient Safety and Tolerability with Longer-Term Exposure to DA-1726 and Further Explore Non-Titrated Maximum Tolerated Dose Top-Line Data Expected i...
MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241
Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential of MetaVia's Oral GPR119 Agonist CAMBRIDGE, Mass. , Aug. 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA...
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass. , July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiom...
MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
CAMBRIDGE, Mass. , June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation ...
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
CAMBRIDGE, Mass. , June 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract h...
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, Waist Reduction and Tolerability Add...
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
CAMBRIDGE, Mass. , May 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a priva...
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment Controlled Attenuation Parameter (CAP) Score Improved by 23.0 dB/m, Indicating Reduced Live...
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
CAMBRIDGE, Mass. , April 23, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract...
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference ...